Spectral Medical Inc. announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as its 19th clinical site for the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults being treated for endotoxemia and septic shock. The Mayo Clinic is a premier medical center in the U.S. and is top ranked in more specialties than any other hospital in the nation, according to U.S. News & World Report.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.485 CAD | -1.02% | -3.00% | +14.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.12% | 99.24M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Inc. Announces Opening of Tigris Clinical Trial Site At the Mayo Clinic